Claire Cayer
Psychiatric/Mental Health · New Bedford, MANPI 1720004476
Payments from drug & device makers
Across 189 payments — averaging $18.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lundbeck LLC$1K
- Otsuka America Pharmaceutical, Inc.$774
- Vanda Pharmaceuticals Inc.$568
- Sunovion Pharmaceuticals Inc.$437
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$252
- Neurocrine Biosciences, Inc.$75
- plus $157 from 4 others
What the payments were for
- Food & beverage$3,552100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lundbeck LLC | 65 | $1,289 |
| Otsuka America Pharmaceutical, Inc. | 38 | $774 |
| Vanda Pharmaceuticals Inc. | 34 | $568 |
| Sunovion Pharmaceuticals Inc. | 25 | $437 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 14 | $252 |
| Neurocrine Biosciences, Inc. | 3 | $75 |
| Corium, LLC | 4 | $51 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $45 |
| AbbVie | 2 | $43 |
| Teva Pharmaceuticals USA, Inc. | 1 | $18 |
How this compares
$3,552 in reported general payments places this provider in the 90th percentile of 1,284 psychiatric/mental health providers in Massachusetts.
See all psychiatric/mental health providers in Massachusetts →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RexultiBrexpiprazole | 24 | $33,137 |
| Lamotrigine ErLamotrigine | 12 | $5,435 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 59 | $2,218 |
| Aripiprazole | 29 | $1,158 |
| Quetiapine Fumarate | 20 | $1,152 |
| Alprazolam | 96 | $860 |
| Clonazepam | 69 | $750 |
| Oxcarbazepine | 28 | $709 |
| Ziprasidone Hcl | 24 | $676 |
| Lorazepam | 93 | $626 |
| Venlafaxine Hcl | 11 | $454 |
| Amitriptyline Hcl | 14 | $416 |
| Bupropion Hcl SrBupropion Hcl | 21 | $408 |
| Benztropine Mesylate | 31 | $373 |
| Escitalopram Oxalate | 22 | $368 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Rexulti | $774 | $33,13724 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,284 psychiatric/mental health providers in Massachusetts.
Other psychiatric/mental health in New Bedford
- Schree PettigrewNew Bedford$18K
- Doreen HuffmanNew Bedford$8K
- Clare KaturamuNew Bedford$5K
- Brianne LienkampMarion$121K
- Ashley BakerQuincy$54K
- Brian BanksPembroke$47K
- Anne-Margaret BotelhoMattapoisett$46K
- Matthew PeculisWalpole$41K
- Sherrie UrenaWorcester$21K
- Irina DauphineeHanover$18K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.